Related Experiment Video
Updated: Apr 6, 2026
Vibratome Sectioning Mouse Retina to Prepare Photoreceptor Cultures
Published on: December 22, 2014
Ciliary neurotrophic factor (CNTF): New facets of an old molecule for treating neurodegenerative and metabolic
Sarah Pasquin1, Mukut Sharma2, Jean-François Gauchat1
1Département de Pharmacologie, Université de Montréal, 2900 Édouard Montpetit, Montreal, QC H3T 1J4, Canada.
Abstract:
Ciliary neurotrophic factor (CNTF) is the most extensively studied member of the cytokine family that signal through intracellular chains of the gp130/LIFRβ receptor. The severe phenotype in patients suffering from mutations inactivating LIFRβ indicates that members of this cytokine family play key, non-redundant roles during development. Accordingly, three decades of research has revealed potent and promising trophic and regulatory activities of CNTF in neurons, oligodendrocytes, muscle cells, bone cells, adipocytes and retinal cells. These findings led to clinical trials to test the therapeutic potential of CNTF and CNTF derivatives for treating neurodegenerative and metabolic diseases. Promising results have encouraged continuation of studies for treating retinal degenerative diseases. Results of some clinical trials showed that side-effects may limit the systemically administrated doses of CNTF. Therefore, therapies being currently tested rely on local delivery of CNTF using encapsulated cytokine-secreting implants. Since the side effects of CNTF might be linked to its ability to activate the alternative IL6Rα-LIFRβ-gp130 receptor, CNTFR-specific mutants of CNTF have been developed that bind to the CNTFRα-LIFRβ-gp130 receptor. These developments may prove to be a breakthrough for therapeutic applications of systemically administered CNTF in pathologies such as multiple sclerosis or Alzheimer's disease. The "designer cytokine approach" offers future opportunities to further enhance specificity by conjugating mutant CNTF with modified soluble CNTFRα to target therapeutically relevant cells that express gp130-LIFRβ and a specific cell surface marker.
Insights
Ciliary neurotrophic factor (CNTF) shows therapeutic promise for neurodegenerative diseases. Modified CNTF variants offer improved safety and targeted delivery, potentially overcoming side effects for conditions like Alzheimer's disease.
Area of Science:
- Biochemistry and Molecular Biology
- Neuroscience
- Cell Biology
Background:
- Ciliary neurotrophic factor (CNTF) is a cytokine signaling through the gp130/LIFRβ receptor, crucial for development.
- Mutations in LIFRβ cause severe phenotypes, highlighting the non-redundant roles of this cytokine family.
- CNTF exhibits trophic and regulatory activities in various cell types, including neurons and retinal cells.
Purpose of the Study:
- To review the therapeutic potential of CNTF and its derivatives for neurodegenerative and metabolic diseases.
- To address the limitations of systemic CNTF administration, such as dose-limiting side effects.
- To explore advancements in CNTF-based therapies, including targeted delivery and engineered mutants.
Main Methods:
- Review of existing research on CNTF's biological activities and signaling pathways.
- Analysis of clinical trial data for CNTF in neurodegenerative and retinal diseases.
- Description of novel approaches like encapsulated cytokine-secreting implants and CNTFR-specific mutants.
Main Results:
- CNTF demonstrates significant therapeutic promise in preclinical and clinical studies for various conditions.
- Systemic administration of CNTF is limited by side effects, necessitating local delivery strategies.
- Development of CNTFR-specific CNTF mutants and targeted delivery systems shows potential to enhance therapeutic efficacy and safety.
Conclusions:
- CNTF holds considerable therapeutic potential, particularly for neurodegenerative and retinal diseases.
- Engineered CNTF variants and targeted delivery methods are crucial for overcoming current therapeutic limitations.
- Future research focusing on "designer cytokines" may revolutionize systemic CNTF applications for diseases like multiple sclerosis and Alzheimer's.
